880759-65-9

880759-65-9 structure

Name: Naloxonazine dihydrochloride
Chemical Name: Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, [(5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene]hydrazone, dihydrochloride, (5α)
CAS Number: 880759-65-9
Molecular Formula: C₃₈H₄₃ClN₄O₆
Molecular Weight: 687.22400
Catalog: Signaling Pathways GPCR/G Protein Opioid Receptor
Create Date: 2016-02-19 06:38:03
Modify Date: 2024-04-01 18:49:59
Naloxonazine dihydrochloride is a specific μ-opioid receptor antagonist with an IC50 of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity[1][2][3].

Name	Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, [(5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene]hydrazone, dihydrochloride, (5α)
Synonyms	NALOXONAZINE DIHYDROCHLORIDE HYDRATE NALOXONAZINE DIHYDROCHLORIDE OPIOID ANTA GONIST Naloxonazine dihydrochloride Demethylasterriquinone B1

Description	Naloxonazine dihydrochloride is a specific μ-opioid receptor antagonist with an IC50 of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity[1][2][3].
Related Catalog	Research Areas >> Infection Signaling Pathways >> GPCR/G Protein >> Opioid Receptor Signaling Pathways >> Neuronal Signaling >> Opioid Receptor Research Areas >> Neurological Disease
Target	μ-opioid receptor:5.4 nM (IC50)
In Vitro	Naloxonazine is relatively stable in solution[2]. Naloxonazine (72 h) is active against the intracellular amastigote stage of Leishmania donovani with a half maximal inhibitory concentration (GI50) of 3.45 μM[3]. Naloxonazine (10 μM; 0-72 h) is active at early stages of Leishmania donovani infection[3]. Naloxonazine affects acidic compartments of the host cell which in turn limit L. donovani intracellular growth[3].
In Vivo	Naloxonazine (20 mg/kg; i.p.; once) attenuates the increment of locomotor activity induced by acute methamphetamine in mice[1] Animal Model: Male ICR mice, methamphetamine (METH)-induced locomotor activity model[1] Dosage: 20 mg/kg Administration: Intraperitoneal injection, once, 60 min before injecting saline (i.p.) or METH (1 mg/kg, i.p.) Result: Significantly attenuated the acute METH-induced increase in locomotor activity and phosphor-Thr75 DARPP-32 levels.
References	[1]. Chien CC, et al. Naloxonazine, a specific mu-opioid receptor antagonist, attenuates the increment of locomotor activity induced by acute methamphetamine in mice. Toxicol Lett. 2012 Jul 7;212(1):61-5. [2]. Hahn EF, et al. Naloxonazine, a potent, long-lasting inhibitor of opiate binding sites. Life Sci. 1982 Sep 20-27;31(12-13):1385-8. [3]. De Muylder G, et al. Naloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded Functions. PLoS Negl Trop Dis. 2016 Dec 30;10(12):e0005234.

Molecular Formula	C₃₈H₄₃ClN₄O₆
Molecular Weight	687.22400
Exact Mass	686.28700
PSA	130.58000
LogP	3.95300

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

82824-01-9	880759-65-9
73625-62-4	20570-96-1
869490-47-1	86694-45-3
157974-36-2	14344-58-2
223132-38-5	63906-90-1
1795191-81-9	1795490-96-8
1795300-77-4	1788533-58-3
1798623-38-7	1795191-91-1
194852-14-7	1788560-46-2
1795491-00-7	1798623-42-3